PO-0681: Randomized phase II study of Erlotinib with radiotherapy in irresectable non small cell lung cancer  by Martinez, E. et al.
S318                                                                                                                                                    ESTRO 35 2016 
______________________________________________________________________________________________________ 
appearance (see table). In these cases, increased D50 values 
were found since the frequency of response was reduced. 
 
 
 
 
 
Conclusion: Radiologic injuries were frequently found in 
follow-up CT scans after RT for NSCLC patients. Logistic 
relationships between the risk of a radiologic response and 
increasing mean lung dose were observed both when 
categorizing the lung injuries in terms of appearance and 
when combining the categories. 
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Purpose or Objective: Although many studies have 
confirmed the synergic effects of combining chemotherapy 
and radiotherapy (RT), clinical data evaluating safety and 
efficacy of erlotinib in combination with RT in locally 
advanced non-small-cell lung carcinoma (NSCLC) are limited. 
This is the first study to determine the feasibility, 
tolerability, and efficacy of the concurrent addition of 
erlotinib to the standard conformal thoracic RT in patients 
with unresectable or locally advanced NSCLC who are not 
candidates for receiving standard CT by any cause. 
 
Material and Methods: 90 patients (p) with irresectable 
NSCLC (I-IIIB stage), ECOG < 2 and measurable disease for 
criteria RECIST were randomized. P assigned to the arm A 
received RT 3D (66 Gy/33 fractions) and P in the arm B 
received the same RT with erlotinib 150 mg/d p.o. 
concurrent up to a maximum of 6 months. The principal aim 
was the G 3-4 toxicity the secondary aims: OS, PFS, cause-
specific survival (CSS), and objective response rate (ORR). 
 
Results: 90 p were included (30 in arm A, 60 in B), 89 were 
valid for safety analysis and 81 of efficacy. Responses: CR 
A/B (%): 21,4/ 41,5 (p <0,05). Median of follow-up 17,1 m. 
OS: 15,3/ 12,9 m (p: NS). CSS: 17,7/ 21,4 m (p: NS). G 3-4 
toxicities: A/B (%): pneumonitis: 10,6/3,3; radiodermitis: 
3/3,3); esofagitis: 0/0; pulmonary fibrosis: 0/3,3; 
cardiopathy: 3,4/1,6; rash: 0/13,3; diarrhea: 3,4/6,7; 
fatigue: 0/8,3. Erlotinib did not increase the toxicity 
produced by the RT. 
 
Conclusion: The combination of erlotinib with RT produces a 
scarce clinical benefit in this group of patients, limited to 
complete responses and longer CSS rate compared with RT 
alone. Increased toxicity events were associated with 
combined therapy, mainly cutaneous toxicity. Further studies 
in molecularly unselected lung cancer patients treated with 
EGFR TKIs and radiotherapy are not indicated. Use of 
predictive biomarkers to identify patients most likely to 
benefit are mandatory 
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Purpose or Objective: To evaluate the sites of relapse and 
prognostic factors of outcome in a retrospective series of 
patients with epithelial thymic tumors (ETT) treated 
consecutively with surgery and post operative RT. 
 
Material and Methods: Data from 134 ETT patients who were 
operated according to guidelines in different centres and 
received RT in Gustave Roussy from 1990 to 2011 was 
retrospectively analysed. Before 1998, patients had 
radiotherapy to the thymic region as well as elective nodal 
radiotherapy (ENRT) to the mediastinum and both supra-
clavicular regions. From 1999 on, patients had conformal RT 
limited to the thymic tumour bed. A 3D-conformal 
radiotherapy (CRT) with CT-based treatment planning was 
used from 1995, and Intensity Modulated Radiotherapy has 
been gradually implemented since 2010 
 
Results: Median follow-up was 8.8 years. Quality of resection 
was R0 in 75%, R1 in 22%, and R2 in 3% of patients. 16% had 
neoadjuvant chemotherapy. Classification according to 
Masaoka-Koga was: stage I/IIA in 17%, IIB in 22%, III in 28%, 
and IV in 33%. 28 patients (21%) had thymic carcinoma 
according to WHO classification. The mean (median? 
delivered dose of RT was 54 Gy (42-66) and 53% patients an 
ENRT at a dose of 45-50 Gy median dose different between 
ENI and CRT. Late toxicities were observed in 16% of patients 
(11 pneumonitis, 9 pericarditis and 6 coronaropathy) but no 
related toxic-death was reported. Considering patterns of 
relapse, there were 26 local relapses which could be 
considered in-field (46% pleura, 27% mediastinum, and 27% to 
both locations) and 42 regional relapses (88% pleura, 5% 
mediastinum, and 7% lung) resulting in a locoregional control 
(LRC) rate of 67%49% at 5/10 years. Distant control rate was 
91% at 10 years. ENI (HR: 2.3) and Masaoka-Koga 
classification > stage IIB (HR: 3.2) were associated with a 
decreased LRC in the multivariate analysis (MVA). Gender, 
age, WHO classification, PS, score, R0 status, CRT dose, and 
boost CRT Were not correlated with LRR in the MVA. The 
cause specific and overall survivals (OS) at 5 and 10 years 
were 72% and 63%, respectively (add 5 year results). PS>0 
(HR: 2.6), and Masaoka-Koga stage IV (HR: 2.1) correlated 
with a lower OS in the MVA. 
 
Conclusion: Masaoka-Koga was the main prognostic factor of 
OS and LRC in this analysis. Indications of RT should be 
